Mesh Bio, MultiOmic Health to Generate AI-Driven Insights on Asian Metabolic Diseases

Singaporean health tech startup Mesh Bio and UK-based drug discovery firm MultiOmic Health have started collaborating to build a huge multi-omics dataset that will provide insights into metabolic syndrome-related conditions among Asians. The large multi-omics dataset they are building will enable the companies to advance their respective R&D programmes to develop precision therapeutic and diagnostic products for patients with metabolic syndrome-related conditions. "Longitudinal multi-omics data combined with deep clinical phenotyping is essential to developing transformative therapeutics and diagnostics in chronic multi-factorial diseases," said Angeli Möller, vice-chairperson and co-founder of the global advocacy group Alliance for Artificial Intelligence in Healthcare.